BioSpaceOriginal article
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Positive
AI Analysis
Summary
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger creating a combined CNS-focused company with 11 approved drugs and expected $2.2 billion in annual revenue, plus $125 million in identified cost savings.
Financial Highlights
Revenue
$2.2 billion
Guidance
$125 million in cost savings
Outcome Details
Merger to create combined entity with 11 approved drugs
Importance:7/10
Sentiment:
0.60
M&AmergerCNScost_savingsapproved_drugs
Read the original article
Published by BioSpace on August 3, 2026 2:15 PM